

17 February 2026

Migraine Treatments

A. How many patients have been treated with the following drugs in the past 4 months:

- **Atogepant (Aiqupta) – any disease**
19 patients
- **Erenumab (Aimovig) - any disease**
No patients, treatment not started
- **Eptinezumab (Vypti) – any disease**
No patients, treatment not started
- **Fremanezumab (Ajovy) - any disease**
No patients, treatment not started
- **Galcanezumab (Emgality) - any disease**
26 patients commenced (this figure does not include review patients)
- **Rimegepant (Vydura) – any disease**
15 patients
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**
155 patients (26 patients in that timeframe receiving 1st cycle)

B. How many patients have you treated in the last 4 months for acute migraine with:

- **Rimegepant (Vydura)**
13 patients

17 February 2026

C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?

Yes